NCT06916975View on ClinicalTrials.gov

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Interventions
DRUG

Adebrelimab

Adebrelimab: 1200mg，iv，d1，q3w；

DRUG

AG

Gemcitabine: 1000 mg/m² ，iv，d1、d8，q3w； Nab-paclitaxel: 125 mg/m² ，iv，d1、d8，q3w；

Trial Locations (1)

Unknown

Fudan University ShangHai Cancer Center, Shanghai

All Listed Sponsors
lead

Jin Xu

OTHER